A new exclusive whitepaper is now available from Lonza entitled ‘Secure your place in the IND race with a rapid tox approach‘. Early tox material can offer valuable clarity as programmes progress toward IND. Lonza’s latest whitepaper introduces a new offering that helps drug developers shorten timelines and generate… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new Technical Note is now available to download, brought to you by Astrea Bioseparations, ‘EtoxiClear, a Chromatography Adsorbent for Effective Removal of Endotoxins from Biopharmaceuticals‘. In this Technical Note you will learn more about: Targeted and efficient endotoxin removal: EtoxiClear is a highly effective chromatography affinity adsorbent, specifically… Read More
In this Technical Note you will learn more about: Targeted and efficient endotoxin removal: EtoxiClear® is a highly effective chromatography affinity adsorbent, specifically designed to remove low residual levels of endotoxins across a variety of biopharmaceutical processes, ensuring high product purity Scalability and cost-effectiveness: Designed for both small and large-scale… Read More
In this webinar hosted by DDW and supported by bit.bio, Dr Stephen Ferguson, Investigator, Mechanistic Toxicology, Division of Translational Toxicology (DTT), National Institute of Environmental Health Sciences, explores the complexities of in vitro modelling for human liver toxicity and pharmacology. He discusses the development… Read More
Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More
Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More
Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More
Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More
Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More
Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are all important for supporting preclinical and clinical pharmaceutical workflows for drug discovery and absorption, distribution, metabolism, excretion, and toxicity (ADMET)… Read More
Around 30% of drugs show adverse reactions during human clinical trials despite promising pre-clinical studies. One of the major causes of the high attrition rate is the poor predictive value of current preclinical models used in drug development. Traditional 2D cell cultures often fail to replicate the cellular… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong looks at the advantages and opportunities 3D cell cultures, organoids and stem cells are bringing to drug discovery teams. The use of 2D biology in the pharmaceutical industry has provided researchers… Read More
